Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

19.750
-0.060-0.30%
Volume:2.73M
Turnover:53.80M
Market Cap:52.52B
PE:13.73
High:19.930
Open:19.610
Low:19.440
Close:19.810
52wk High:29.000
52wk Low:12.535
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:1.83
T/O Rate:0.50%
Dividend:0.35
Dividend Rate:1.77%
EPS(LYR):1.439
ROE:6.98%
ROA:1.47%
PB:0.95
PE(LYR):13.73
PS:1.11

Loading ...

Fosun Pharma (600196.SH / 02196.HK) Receives Acceptance for Additional Indication of Luvometinib Tablets

Bulletin Express
·
Feb 05

Fosun Pharma's Subsidiary Henlius Enters Licensing Agreement with Eisai for Cancer Treatment

Stock News
·
Feb 05

Fosun Pharma (02196) Announces Proposed Spin-off of Fosun Adgenvax

Bulletin Express
·
Feb 04

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196): Notice of 2026 First Class Meeting of H Shareholders

Bulletin Express
·
Feb 04

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Stock Code: 02196) Publishes 2026 First EGM and H Shareholders’ Class Meeting Circular

Bulletin Express
·
Feb 04

Fosun Pharma Sells 1 Billion Yuan Bonds

MT Newswires Live
·
Feb 03

Fosun Pharma (02196) Completes Issuance of First Tranche of 2026 Scientific and Technological Innovation Bonds

Bulletin Express
·
Feb 03

Fosun Pharma Plans to Spin Off Vaccine Subsidiary for Hong Kong Listing, Reports 2024 Loss of 120 Million Yuan

Deep News
·
Jan 23

BUZZ-Shanghai Fosun Pharmaceutical climbs on vaccine unit's Hong Kong listing plan

Reuters
·
Jan 23

Fosun Pharmaceutical Unit Wins China Approval for Norepinephrine Injection

MT Newswires Live
·
Jan 23

Shanghai Fosun Pharmaceutical (02196) Announces Proposed Spin-Off of Fosun Adgenvax for Main Board Listing

Bulletin Express
·
Jan 22

Fosun Pharmaceutical Gets Nod for Colorectal Cancer Drug Clinical Trial

MT Newswires Live
·
Jan 21

InSilico Medicine Signs CNS Drug Deal With Hygtia Therapeutics; Shares Up 4%

MT Newswires Live
·
Jan 20

Fosun Pharma Unit Gets China Acceptance for Lung Cancer Drug Application

MT Newswires Live
·
Jan 08

Fosun Pharma's (600196.SH) Controlled Subsidiary Has Drug Registration Application Accepted

Stock News
·
Jan 08

Fosun Pharmaceutical-Backed Fund Completes Private Fund Filing

MT Newswires Live
·
Jan 06

Hong Kong Stock Announcement Highlights | Everest MED: Original Product Nefecon® Technology Protected by Valid Chinese Patent ZL200980127272.5

Stock News
·
Dec 30, 2025

Fosun Pharma's 1.4 Billion Yuan Bet on Discontinued Drug Draws Scrutiny Amid Efficacy Doubts

Deep News
·
Dec 23, 2025

Fosun Pharma's $1.4B Bet on Controversial Alzheimer's Drug: What's the Strategy?

Deep News
·
Dec 21, 2025

Fosun Pharma, ClavisBio Sign Five-Year Drug Collaboration Agreement; Shanghai Shares Rise 3%

MT Newswires Live
·
Dec 19, 2025